Squarepoint
RVLP

Squarepoint’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

Squarepoint’s Portfolio RVLP Stock Details RVLP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,299
Closed -$12.9K – 4168
2023
Q1 		$12.9K Buy
+11,299
New +$13.6K ﹤0.01% 3144
2021
Q3 		– Sell
-80,827
Closed -$243K – 3599
2021
Q2 		$243K Sell
80,827
-85,336
-51% -$261K ﹤0.01% 2676
2021
Q1 		$542K Buy
+166,163
New +$683K ﹤0.01% 1954
2020
Q4 		– Sell
-58,102
Closed -$314K – 3361
2020
Q3 		$314K Buy
+58,102
New +$335K ﹤0.01% 1761
2020
Q2 		– Sell
-173,385
Closed -$551K – 2599
2020
Q1 		$551K Buy
173,385
+108,962
+169% +$580K 0.01% 986
2019
Q4 		$450K Buy
+64,423
New +$344K ﹤0.01% 1832

Other funds holding RVLP

ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
RA
Rovida Advisors Fort Lauderdale, Florida $116M AUM 12.52% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Squarepoint's RVLP Position: Q2 2023 in Review

Squarepoint sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q2 2023, closing a stake of 11,299 shares — an estimated $12.9K sold.

Squarepoint first reported a position in RVLP in Q4 2019 and held it in 6 quarters. The position peaked at $551K in Q1 2020. 36 funds tracked by Wall St. Rank hold RVLP as of Q2 2023.

  • Squarepoint reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q2 2023 after selling out during the quarter.
  • Squarepoint sold 11,299 RVL Pharmaceuticals plc Ordinary Shares shares in Q2 2023, an estimated $12.9K.
  • Squarepoint first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q4 2019 and held it in 6 quarters.
  • Squarepoint's RVL Pharmaceuticals plc Ordinary Shares position peaked at $551K in Q1 2020.
  • 36 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q2 2023.

Based on Squarepoint's 13F filing for Q2 2023, filed 14 Aug 2023.